Syngenta

Last updated January 31, 2026

Innovation Areas

1,941

Inventors

Collaborations

Crystalline polymorph phase control: SyngentaRecent Research Landscape

Unpredictable phase transitions during manufacturing compromise drug solubility and shelf-life stability. Precise engineering of specific crystalline lattices ensures consistent bioavailability and regulatory compliance.

What technical problems is Syngenta addressing in Crystalline polymorph phase control?

Unpredictable solid state instability

(5)evidences

Inconsistent crystalline structures lead to variations in solubility and bioavailability. Controlling phase purity prevents unintended changes in therapeutic efficacy.